Cargando…

Subacute toxicity evaluations of LPM3480392 in rats, a full µ-opioid receptor biased agonist

Opiates produce analgesia via G-protein signaling, and adverse effects, such as respiratory depression and decreased bowel motility, by β-arrestin pathway. Oliceridine, a G protein-biased MOR agonist, only presents modest safety advantages as compared to other opiates in clinical trials, possibly du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Liang, Li, Chunmei, Jiang, Wanglin, Yang, Yifei, Wang, Wenyan, Zhu, Haibo, Hu, Zhengping, Li, Ning, Cen, Xiaobo, Wang, Hongbo, Tian, Jingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436550/ https://www.ncbi.nlm.nih.gov/pubmed/37601058 http://dx.doi.org/10.3389/fphar.2023.1218380

Ejemplares similares

LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
por: Li, Nannan, et al.
Publicado: (2019)

Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor
por: Zhang, Fangxi, et al.
Publicado: (2016)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Synthesis and Evaluation of Novel Biased μ-Opioid-Receptor (μOR) Agonists
por: Ma, Mengjun, et al.
Publicado: (2019)

First indication of LPM effect in LHCf, an LHC experiment
por: del Prete, M
Publicado: (2016)

Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine
por: Webster, Lynn, et al.
Publicado: (2016)

Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
por: Zhu, Haibo, et al.
Publicado: (2021)

LPM-Effect in Monte Carlo Models of Radiative Energy Loss
por: Zapp, Korinna C, et al.
Publicado: (2009)

Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist
por: Doi, Seira, et al.
Publicado: (2016)

Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist
por: Zebala, John A., et al.
Publicado: (2020)

Structure‐Based Evolution of G Protein‐Biased μ‐Opioid Receptor Agonists
por: Wang, Haoqing, et al.
Publicado: (2022)

Oral Presentations (LDD, LPES, LNM, LPAT, LNT, LPPT, LPM)
Publicado: (2010)

Complete Genome Sequence of the Probiotic Strain Lactobacillus salivarius LPM01
por: Chenoll, Empar, et al.
Publicado: (2016)

Influence of G protein-biased agonists of μ-opioid receptor on addiction-related behaviors
por: Kudla, Lucja, et al.
Publicado: (2021)

Implementation of the LPM effect in the discrete-bremsstrahlung simulation of GEANT3 and GEANT4
por: Mangiarotti, A, et al.
Publicado: (2008)

Investigation of the Wind-Induced Airflow Pattern Near the Thies LPM Precipitation Gauge
por: Chinchella, Enrico, et al.
Publicado: (2021)

Activation of the μ‐opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure
por: Åstrand, Anna, et al.
Publicado: (2020)

Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor
por: Cong, Xiaojing, et al.
Publicado: (2015)

μ-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges
por: Salinsky, Leah M., et al.
Publicado: (2023)

Full Opioid Agonists and Tramadol: Pharmacological and Clinical Considerations
por: Edinoff, Amber N., et al.
Publicado: (2021)

Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid Receptor Agonist
por: Li, Xin, et al.
Publicado: (2017)

The Hypnotic, Anxiolytic, and Antinociceptive Profile of a Novel µ-Opioid Agonist
por: Montes, Guilherme Carneiro, et al.
Publicado: (2017)

Comparison of an Addictive Potential of μ-Opioid Receptor Agonists with G Protein Bias: Behavioral and Molecular Modeling Studies
por: Kudla, Lucja, et al.
Publicado: (2021)

Coherent and incoherent radiation from high-energy electron and the LPM effect in oriented single crystal
por: Baier, V N, et al.
Publicado: (2005)

New concept of pump-less forward osmosis (FO) and low-pressure membrane (LPM) process
por: Im, Sung-Ju, et al.
Publicado: (2017)

The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist
por: Gassaway, M M, et al.
Publicado: (2014)

Linear programming based gene expression model (LPM-GEM) predicts the carbon source for Bacillus subtilis
por: Thanamit, Kulwadee, et al.
Publicado: (2022)

A Facile Synthesis for Novel Loperamide Analogs as Potential μ Opioid Receptor Agonists
por: Bao, Xiaofeng, et al.
Publicado: (2012)

The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
por: Skoglund, Charlotte, et al.
Publicado: (2022)

Computational Drug Design of Novel Agonists of the μ -Opioid Receptor to Inhibit Pain Signaling
por: Daoud, Nancy, et al.
Publicado: (2023)

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review
por: Soyka, Michael
Publicado: (2021)

The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats
por: Zhang, Renyu, et al.
Publicado: (2014)

N-Phenethyl Substitution in 14-Methoxy-N-methylmorphinan-6-ones Turns Selective µ Opioid Receptor Ligands into Dual µ/δ Opioid Receptor Agonists
por: Dumitrascuta, Maria, et al.
Publicado: (2020)

Three-Dimensional Structural Insights Have Revealed the Distinct Binding Interactions of Agonists, Partial Agonists, and Antagonists with the µ Opioid Receptor
por: Li, Zoe, et al.
Publicado: (2023)

Effect of Tramadol (μ-opioid receptor agonist) on orthodontic tooth movements in a rat model
por: Rashidpour, M., et al.
Publicado: (2012)

The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception
por: Hill, Rob, et al.
Publicado: (2018)

Toward a Universal μ-Agonist Template for Template-Based Alignment Modeling of Opioid Ligands
por: Wu, Zhijun, et al.
Publicado: (2019)

Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment
por: Wang, Yunjie, et al.
Publicado: (2023)

Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method
por: Hämmig, Robert, et al.
Publicado: (2016)

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
por: Levy-Cooperman, N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_anfbcrfbmogiaa3sn5ap8o5ad8